TVGN-489
COVID-19 (treatment)
Key Facts
About Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company leveraging its patented ExacTcell technology to harness CD8+ cytotoxic T lymphocytes for the development of allogeneic, precision T cell therapies. Its lead candidate, TVGN-489, is in clinical development for COVID-19, with a pipeline extending to oncology and neurology. The company's vision centers on affordability and broad patient access, supported by a scalable manufacturing process and an AI-driven predictive technology arm, Tevogen.AI.
View full company profileAbout Tevogen Bio
Tevogen Bio is a clinical-stage specialty immunotherapy company leveraging its patented ExacTcell technology to harness CD8+ cytotoxic T lymphocytes for the development of allogeneic, precision T cell therapies. Its lead candidate, TVGN-489, is in clinical development for COVID-19, with a pipeline extending to oncology and neurology. The company's vision centers on affordability and broad patient access, supported by a scalable manufacturing process and an AI-driven predictive technology arm, Tevogen.AI.
View full company profile